Lee Gary K. sold $23K of LYEL
Lee Gary K. (Chief Scientific Officer) sold 1,457 shares of Lyell Immunopharma, Inc. (LYEL) at $15.54 on 2026-08-21.
How this was made
The 30-second read
Why it matters
The sale is routine and does not signal a shift in company strategy or financial health.
Market read
A small insider sell with limited trading relevance; unlikely to affect LYEL price.
What to watch
Potential upcoming clinical data releases could change perception of insider activity.
Background
Form 4 filings provide transparent reporting of insider transactions required by the SEC.
Ticker impact
SEC Form 4 disclosed Chief Scientific Officer Lee Gary K. sold 1,457 shares for $22,642, reducing his stake to 16,220 shares.
No significant price impact expected.
The transaction size is small relative to market cap and typical insider activity; no change in control or strategic direction.
Market effects
None; biotech sector unchanged.
None; limited to US market.
None
Counterpoint
If the insider anticipates near‑term weakness, a short‑term dip could be considered.
Key entities
- CompanyLyell Immunopharma, Inc.
Biotech firm developing immunotherapies, ticker LYEL.
- InsiderLee Gary K.
Chief Scientific Officer of Lyell Immunopharma.